ReviewBiomolecules & biomedicine2025
Anti-Müllerian hormone in PCOS: Molecular regulation and emerging therapeutic strategies.
Review in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Molecular Mechanisms Underlying Reproductive Dysfunction in Polycystic Ovary Syndrome.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Molecular mechanisms and multi-organ regulatory roles of anti-Müllerian hormone in female reproduction.Communications biology · 2026Review
- Review
- Changes in ovarian reserve function after laparoscopic ovarian cystectomy: a retrospective cohort study.Frontiers in surgery · 2026Article
- Lobetyolin reshapes gut microbiota and bile acid metabolism to improve androgen-driven PCOS phenotypes in mice.Frontiers in microbiology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-Müllerian hormone (AMH), a glycoprotein belonging to the transforming growth factor-beta (TGF-β) superfamily, is a key regulator of ovarian folliculogenesis. Dysregulated AMH expression is a hallmark of polycystic ovary syndrome (PCOS), a common endocrine and metabolic disorder characterized by hyperandrogenism, anovulation, and polycystic ovarian morphology. Elevated AMH levels in PCOS impair follicle-stimulating hormone (FSH) sensitivity, disrupt follicular maturation, and contribute to androgen excess-creating a feedback loop that exacerbates ovarian dysfunction. This review explores the complex regulatory mechanisms governing AMH expression, including transcriptional, post-transcriptional, and post-translational processes. It highlights the interplay between AMH, FSH, and androgen signaling pathways, emphasizing their roles in the pathophysiology of PCOS. Particular attention is given to the downstream SMAD-dependent signaling cascade, which mediates many of AMH's biological effects. Additionally, we summarize emerging therapeutic strategies targeting AMH signaling, such as AMHR2 (anti-Müllerian hormone receptor type 2) antagonists, GnRH (gonadotropin-releasing hormone) antagonists, and aromatase inhibitors. A deeper understanding of AMH regulation and signaling provides critical insights into its role in PCOS progression and supports the development of novel, targeted treatments aimed at alleviating both reproductive and metabolic symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.